secwatch / observer
8-K filed May 21, 2026, 4:20 PM ET CIK 0001957845
other material confidence high sentiment neutral materiality 0.50

KKR Private Equity Conglomerate reports April 30 NAV per share range $34.18-$37.19, total $11.56B

KKR Private Equity Conglomerate LLC

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001957845-26-000043
form_type
8-K
ticker
null
cik
0001957845
company_name
KKR Private Equity Conglomerate LLC
filed_at
2026-05-21T20:20:26+00:00
discovered_at
2026-05-21T20:21:00.286387+00:00
generated_at
2026-05-21T20:21:36.573390+00:00
sec_items
["8.01", "9.01"]
event_type
other_material
sentiment
neutral
materiality_score
0.5
calibrated_materiality_score
0.5
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001957845-26-000043
json_url
https://secwatch.observer/filing/0001957845-26-000043.json
markdown_url
https://secwatch.observer/filing/0001957845-26-000043.md
text_url
https://secwatch.observer/filing/0001957845-26-000043.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1957845/000195784526000043/0001957845-26-000043-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1957845/000195784526000043/kkr-20260521.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null

Comparable filings

EMYB

Embassy Bancorp expands stock repurchase program by additional $5M

Embassy Bancorp, Inc. June 1, 2026, 4:37 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CTXR

Citius Oncology reports Phase 1 combo data: 24% ORR, 33% in endometrial cancer; Phase 2 planned

Citius Pharmaceuticals, Inc. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CTOR

Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer

CITIUS ONCOLOGY, INC. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

SYRE

Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030

Spyre Therapeutics, Inc. June 1, 2026, 4:01 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

ORKA

Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030

Oruka Therapeutics, Inc. June 1, 2026, 4:01 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

VIASP

Via Renewables to redeem all 1,884,935 shares of its 8.75% Series A Preferred at $25.00 per share plus dividends

Via Renewables, Inc. June 1, 2026, 3:06 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

BUKS

CEO Christopher Reedy discloses ongoing cancer treatment; remains in role

BUTLER NATIONAL CORP June 1, 2026, 12:41 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CPSH

CPS Technologies closes $9.6M registered direct offering of 1.2M shares at $8.00/share

CPS TECHNOLOGIES CORP/DE/ June 1, 2026, 9:35 AM ET other_material Items 1.01, 5.03, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR
accession 0001957845-26-000043

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.